Market Research Logo

Global Monoclonal Antibodies Market 2016-2020

About Monoclonal Antibodies

Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell. They are complex proteins with high molecular weight, and were first developed in 1975 by Kohler and Milstein.

Technavio’s analysts forecast the global monoclonal antibodies (mAbs) market to grow at a CAGR of 9.84% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded mAbs and biosimilars used to treat cancer, autoimmune and inflammatory diseases, respiratory diseases, and ophthalmology. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market, along with the decline in revenues from the patent expiries of the marketed drugs, during the forecast period.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
Other prominent vendors
  • AbGenomics
  • ADC Therapeutics
  • Agensys
  • Alexion Pharmaceuticals
  • ALMAC Group
  • Ambrx
  • Astellas Pharma
  • AstraZeneca
  • Bayer HealthCare
  • Biogen
  • Celgene
  • Celldex Therapeutics
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Formation Biologics
  • Genmab
  • GlaxoSmithKline
  • Human Genome Sciences
  • Immunogen
  • MedImmune
  • Novartis
  • Pfizer
  • Seattle Genetics
  • Stemcentrx
  • Synthon Biopharmaceuticals
  • Takeda Pharmaceuticals
  • Teva
  • UCB
Market driver
  • Special regulatory drug designations
  • For a full, detailed list, view our report
Market challenge
  • High manufacturing costs coupled with stringent regulations
  • For a full, detailed list, view our report
Market trend
  • Growing focus of vendors on untapped markets
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Monoclonal Antibodies (mAbs) Market 2016-2020

Technavio recognizes the following companies as the key players in the global monoclonal antibodies (mAbs) market: AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, and Merck.

Other Prominent Vendors in the market are: AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, and UCB.

Commenting on the report, an analyst from Technavio’s team said: “The emergence of biosimilars will be a key trend leading to the market growth. In recent years, the population of the aging has increased due to the availability of advanced medical care. This rising aging population has also increased the prevalence of various chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers and metabolic disorders, leading to a high demand for quality care. Biosimilars will likely play a prominent role in this scenario.”

According to the report, one of the key drivers for market growth will be special regulatory drug designations. The US FDA's Office of Orphan Products Development (OOPD) aims to develop and evaluate drugs, biologics, and devices that effectively treat and diagnose rare diseases or conditions, and provides incentives to companies that develop drugs for rare disorders. It also grants orphan status to drugs and biologics proven to be effective and safe in treating rare diseases.

Further, the report states that threat from chemotherapy and off-label drugs will be one of the challenges faced by the market. Cytotoxic chemotherapy is used by physicians worldwide to treat cancer. Chemotherapy drugs most often used to treat cancer are chlorambucil, fludarabine, cyclophosphamide, and bendamustine. Fludarabine is administered in combination with cyclophosphamide (a fixed combination (FC) regimen). In some cases, rituximab is also given along with the FC regimen. Sometimes, a combination of chemotherapy drugs is administered. Off-label drug use is frequently seen in treating cancers, inflammatory diseases, and respiratory diseases.

Companies Mentioned

AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Merck, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, UCB.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key buying criteria for mAbs 2015
      • Table Impact of key customer segments on market 2015
  • mAbs: Overview
    • Evolution of mAb therapeutics
      • Table Comparison of small molecule and mAbs
      • Table Preparation of mAbs
    • Types of mAbs
      • Table Types of mAbs
    • Conjugated cancer therapies using mAbs
      • Table Targeted mechanisms of cancer mAbs
  • Market landscape
    • Market overview
      • Table Patent expiries of top selling mAbs by 2020 in US
      • Table Patent expiries of top selling mAbs by 2020 in Europe
      • Table Global mAbs market snapshot: Developed and emerging markets 2015
      • Table Global mAbs market 2015-2020 ($ billions)
      • Table Few patient assistance programs offered by various companies
      • Table Few awareness programs for various cancers, respiratory, and ophthalmology diseases
      • Table Impact of drivers and challenges on global mAbs market
      • Table Competitive assessment of marketed and late-stage pipeline molecules
      • Table Opportunities in mAbs industry today
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of mAbs
    • Naked mAbs
      • Table Approved naked mAbs by US FDA and EU
    • Conjugated mAbs
  • Market segmentation by application
    • Table Global mAbs market: Segmentation by application (2015-2020)
    • Table Global mAbs market: Segmentation by application 2015
    • Table Global mAbs market segmentation: Growth cycle analysis
    • Global oncology mAbs market
      • Table Annual treatment cost per patient for various oncology drugs 2014
      • Table Global oncology mAbs market 2015-2020 ($ billions)
      • Table Opportunity analysis of global oncology mAbs market by type of application
      • Table Market segmentation by MOA
    • Global autoimmune and inflammatory mAbs market
      • Table Population aged 60 years and over (millions)
      • Table Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
      • Table Global autoimmune and inflammatory mAbs market 2015-2020 ($ billions)
      • Table Opportunity analysis of global autoimmune and inflammatory mAbs market by application
      • Table Global autoimmune and inflammatory mAbs market segmentation by MOA
    • TNF inhibitors
      • Table Average percentage of patients receiving TNF inhibitors 2010 and 2015
    • IL-1 blockers
    • PDE4 inhibitors
      • Table Global autoimmune and inflammatory mAbs market share by MOA 2015
    • Global respiratory mAbs market
      • Table Global respiratory mAbs market 2015-2020 ($ billions)
      • Table Opportunity analysis of global respiratory mAbs market by application
      • Table Global mAbs market segmentation by application 2015
    • Global ophthalmology mAbs market
      • Table Global ophthalmology mAbs market 2015-2020 ($ billions)
      • Table Opportunity analysis of global ophthalmology mAbs market by application
  • Geographical segmentation
    • Global mAbs market by geographical segmentation 2015-2020
      • Table Global mAbs market: Geography outlook (2015-2020)
      • Table Global mAbs market: Geography outlook 2015
      • Table Revenue/growth outlook in different countries/regions 2015
    • mAbs market in Americas
      • Table mAbs market in Americas 2015-2020 ($ billions)
      • Table mAbs market in Americas by country 2015
    • mAbs market in US
      • Table mAbs market in US 2015-2020 ($ billions)
    • mAbs market in EMEA
      • Table mAbs market in EMEA 2015-2020 ($ billions)
      • Table mAbs market in EMEA by country 2015
    • mAbs market in APAC
      • Table Number of individuals treated with Herceptin through patient assistance programs in China 2011-2014
      • Table mAbs market in APAC 2015-2020 ($ billions)
      • Table mAbs market in APAC by country 2015
      • Table Global mAbs market by geographical segmentation 2015
      • Table Global mAbs market by geographical segmentation 2020
      • Table Global mAbs market revenue by geography 2015-2020 ($ billions)
  • Key leading countries
    • Table Key leading countries
  • Pipeline portfolio
    • Table Pipeline share of global mAbs market 2015
    • Table Phase III pipeline molecules for mAbs
    • Table Phase II pipeline molecules for mAbs
    • Table Phase I pipeline molecules for mAbs
  • Market drivers
    • Reimbursement benefits for mAbs and its biosimilars
    • Special regulatory drug designations
      • Table Special regulatory designations approved by US FDA
      • Table Special regulatory designations approved by EU
    • Increase in demand for ADCs
    • Increase in industry-academia collaborations
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Absence of adequate diagnosis and screening procedures
    • High manufacturing costs coupled with stringent regulations
    • Threat from chemotherapy and off-label drugs
    • Difficulties in patient recruitment for conducting clinical trials
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of biosimilars
    • Growing focus of vendors on untapped markets
    • Focus on novel mechanisms
    • Joint ventures and partnerships for R&D
    • Emergence of targeted and combination therapies
      • Table Expected combination regimen launches in oncology
      • Table Global mAbs market: Impact assessment of top trends 2015
  • Vendor landscape
    • Competitive scenario
      • Table Market presence of vendors in various therapy areas 2015
      • Table Market share analysis 2015
      • Table YoY sales comparison of top ten mAbs 2013-2015 ($ billions)
      • Table Competitive assessment of vendors
      • Table Key vendors: Geographical presence 2015
    • Key news
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Lucentis 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Xolair 2013-2015 ($ billions)
      • Table F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Kadcyla 2015
      • Table Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
      • Table Actemra/RoActemra geographic segmentation by revenue 2015
      • Table F Hoffmann-La Roche: Metrics analysis
    • AbbVie
      • Table AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of Humira (US) 2013-2015 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
      • Table AbbVie: YoY revenue and growth rate of Synagis 2013-2015 ($ millions)
      • Table AbbVie: Metrics analysis
    • Johnson & Johnson
      • Table Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Remicade (US) 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Stelara (US) 2013-2015 ($ millions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ millions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (US) 2013-2015 ($ millions)
      • Table Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2013-2015 ($ millions)
      • Table Johnson & Johnson: Metrics analysis
    • Amgen
      • Table Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
      • Table Amgen: Geographic segmentation of Xgeva 2015
      • Table Amgen: YoY growth and revenue generated from net product sales of Prolia 2013-2015 ($ billions)
      • Table Amgen: Geographical segmentation of Prolia 2015
      • Table Amgen: YoY growth and revenue generated from net product sales of Vectibix 2013-2015 ($ millions)
      • Table Amgen: Geographical segmentation of Vectibix 2015
      • Table Amgen: Metrics analysis
    • Merck
      • Table Merck: YoY revenue and growth rate of Remicade (Europe, Russia, and Turkey) 2013-2015 ($ billions)
      • Table Merck: YoY revenue and growth rate of Simponi (Europe, Russia, and Turkey) 2013-2015 ($ millions)
      • Table Merck: Metrics analysis
    • BMS
      • Table BMS: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ billions)
      • Table BMS: Geographical segmentation of Yervoy 2015
      • Table BMS: YoY Revenue and growth rate of Erbitux in US and Canada 2013-2015 ($ millions)
      • Table BMS: Geographical segmentation of Yervoy 2015
      • Table BMS: Geographical segmentation of Opdivo 2015
      • Table BMS: Metrics analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report